# Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

> **NCT03689582** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 68Ga-PSMA

## Key facts

- **NCT ID:** NCT03689582
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-13
- **Primary completion:** 2020-02-27
- **Final completion:** 2020-02-27
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** due to pandemic related constraints
- **Last updated:** 2022-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03689582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03689582, "Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03689582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*